IMUKIN interferon gamma-1b recombinant human 2 million IU (100 micrograms)/0.5mL injection vial, Link Medical Products Pty Ltd , CON-1463
Product name
IMUKIN interferon gamma-1b recombinant human 2 million IU (100 micrograms)/0.5mL injection vial
Sponsor name
Link Medical Products Pty Ltd
Batches
M005848
Consent start
Consent no.
CON-1463
Duration
The consent is effective from 25 February 2026 until 28 February 2027.
Standard
Paragraphs 8(1)(a), 9(1)(a), 8(1)(c), 9(1)(c), 9(3)(a), 10(4)(j), 11(5)(iii), subparagraph 10(3)(a)(i) invoked by paragraph 10(4)(b), paragraph 19(3)(b) invoked by paragraph 10(4)(b), subparagraphs 11(1)(a)(i), 11(3)(a)(i) and 11(3)(a)(ii) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The name of the medicine supplied in the UK (IMMUKIN) is spelt differently to
the Australian (AU) name (IMUKIN). The quantity or proportion of all active
ingredients in the medicine. The strength on the UK labelling (2x10^6 IU (0.1
mg)) is presented differently on the AU labelling (2 million IU (100
microgram)). The name of the medicine and the name(s) of active ingredient(s) on
the main label must appear as a cohesive unit by the placing of the name and
quantity of each active ingredient together on separate lines of text. The name
of the active ingredient and quantity of active ingredient are not in a cohesive
unit. The name and quantity of each excipient in the medicine, expressed for
single dose injections (including concentrated solutions for injection) - as the
nominal mass of that excipient (not including any overage) in the stated volume
of fill of the injection in the container. No details of excipient masses are
presented and Australian approved names are not used for all excipients. Where
the medicine is supplied in a container with potential for multidose use, such
as a vial or pre-filled syringe, and an antimicrobial preservative is not
included in the medicine - the statement ‘Use in one patient on one occasion
only. Contains no antimicrobial preservative’ or words to that effect. No
wording for this requirement is presented. The name of the sponsor or
distributor as it appears on the primary pack, or registered trademark if it
readily identifies the sponsor or distributor of the medicine. The name of the
sponsor is not included on the vial label. A statement of quantity for 1
microgram up to 999 micrograms inclusive must be expressed in terms of
micrograms. The strength of the active on the UK labelling is presented as 0.1
mg and not 100 micrograms. For a liquid biological medicine or a biological
medicine required to be prepared before use, the potency: must be included on
the label of the medicine; and must be expressed as potency units, or weight of
active ingredient per dose or per unit volume, or as the volume which contains
the recommended dose. Potency is not expressed in this manner. ‘Store at 2°C to
8°C (Refrigerate. Do not freeze)’. The storage information is not displayed as
one of the "permitted statement of storage temperature conditions”.
Conditions imposed
The UK stock to cover the medicine shortage is identical to the Australian
registered product. There will be a sticker including the AUST R number and
Sponsor's details attached to the product labels for physician/patient.
Arrangements are in place to include a health care professional letter with
IMUKIN dispensed by relevant pharmacies.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines